The Kv7 channel opener Retigabine reduces neuropathology and alleviates behavioral deficits in APP/PS1 transgenic mice
Behavioural Brain Research · 2024-08 · 471 · 115137
DOI: 10.1016/j.bbr.2024.115137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Behavioural Brain Research, 2024-08. Verfasst von Dongpei Zhuang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Qingdao University Qingdao Medical College, China. Electronic address: DongpeiZhuangQDU@163.com. Hauptthemen laut MEDLINE: Phenylenediamines, Carbamates, Alzheimer Disease, Mice, Transgenic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Project of Shandong Province Higher Educational Science and Technology Program, Science and Technology Planning Project of Guangdong Province, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Hyperexcitability of neuronal networks is central to the pathogenesis of Alzheimer's disease (AD). Pharmacological activation of Kv7 channels is an effective way to reduce neuronal firing. Our results showed that that pharmacologically activating the Kv7 channel with Retigabine (RTG) can alleviate cognitive impairment in mice without affecting spontaneous activity. RTG could also ameliorate damage to the Nissl bodies in cortex and hippocampal CA and DG regions in 9-month-old APP/PS1 mice. Additionally, RTG could reduce the Aβ plaque number in the hippocampus and cortex of both 6-month-old and 9-month-old mice. By recordings of electroencephalogram, we showed that a decrease in the number of abnormal discharges in the brains of the AD model mice when the Kv7 channel was opened. Moreover, Western blot analysis revealed a reduction in the expression of the p-Tau protein in both the hippocampus and cortex upon Kv7 channel opening. These findings suggest that Kv7 channel opener RTG may ameliorate cognitive impairment in AD, most likely by reducing brain excitability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, Qingdao University Qingdao Medical College, China. Electronic address: DongpeiZhuangQDU@163.com.
- Department of Pharmacy, Qingdao Eighth People's Hospital, China. Electronic address: 18663930630@163.com.
- Department of Pharmacology, School of Pharmacy, Qingdao University Qingdao Medical College, China. Electronic address: 15666136590@163.com.
- Department of Pharmacology, School of Pharmacy, Qingdao University Qingdao Medical College, China. Electronic address: zhangxinyao0810@163.com.
- Department of Pharmacology, School of Pharmacy, Qingdao University Qingdao Medical College, China. Electronic address: jucx@qdu.edu.cn.
Förderung
- Project of Shandong Province Higher Educational Science and Technology Program
- Science and Technology Planning Project of Guangdong Province
- Natural Science Foundation of Shandong Province
- Ministry of Science and Technology of the People's Republic of China
Zitieren
APA
Zhuang, D., Yu, N., Han, S., Zhang, X., & Ju, C. (2024). The Kv7 channel opener Retigabine reduces neuropathology and alleviates behavioral deficits in APP/PS1 transgenic mice. Behavioural Brain Research, 471, 115137. https://doi.org/10.1016/j.bbr.2024.115137
Vancouver
Zhuang D, Yu N, Han S, Zhang X, Ju C. The Kv7 channel opener Retigabine reduces neuropathology and alleviates behavioral deficits in APP/PS1 transgenic mice. Behavioural Brain Research. 2024;471:115137. doi:10.1016/j.bbr.2024.115137
BibTeX
@article{Zhuang2024,
author = {Zhuang, Dongpei and Yu, Nan and Han, Shuo and Zhang, Xinyao and Ju, Chuanxia},
title = {The Kv7 channel opener Retigabine reduces neuropathology and alleviates behavioral deficits in APP/PS1 transgenic mice},
journal = {Behavioural Brain Research},
year = {2024},
volume = {471},
pages = {115137},
doi = {10.1016/j.bbr.2024.115137}
}
EUVIMED